{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:49:12Z","timestamp":1785944952798,"version":"3.56.0"},"reference-count":25,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There are limited data describing the epidemiology, management and outcomes of children with toxic shock syndrome (TSS), a potentially life-threatening illness. Here, we describe the incidence, clinical features, treatment and outcome of children with staphylococcal and streptococcal TSS in Victoria, Australia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective chart review of children admitted between 2003 and 2014 to two tertiary paediatric referral centres who fulfilled the Centers for Disease Control and Prevention case definition of TSS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 62 cases over the 11-year period; 43 staphylococcal TSS and 19 streptococcal TSS. The majority (46 (74%)) of cases were admitted to an intensive care unit and 44 (71%) required inotropic support. Compared with those with staphylococcal TSS, patients with streptococcal TSS were younger, more unwell and more likely to have residual morbidity. Adjunctive therapy with intravenous immunoglobulin or clindamycin was used in 58 (94%) of cases and fresh frozen plasma was used in 15 (24%). Seven patients received extracorporeal membrane oxygenation. All patients survived.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study highlights the importance of early recognition of TSS and supports rapid tertiary referral and intensive care management, which includes the use of adjunctive therapy with intravenous immunoglobulin and clindamycin.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2015-310121","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T04:24:27Z","timestamp":1461731067000},"page":"736-740","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["Toxic shock syndrome in Australian children"],"prefix":"10.1136","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-8031","authenticated-orcid":false,"given":"Katherine Y H","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Burgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,4,26]]},"reference":[{"key":"key-10.1136\/archdischild-2015-310121-1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(09)70066-0","article-title":"Gram-positive toxic shock syndromes","volume":"9","author":"Lappin","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molmed.2013.10.004","article-title":"Streptococcal superantigens: categorization and clinical associations","volume":"20","author":"Commons","year":"2014","journal-title":"Trends Mol Med"},{"key":"key-10.1136\/archdischild-2015-310121-3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1473-3099(02)00222-0","article-title":"Superantigens: microbial agents that corrupt immunity","volume":"2","author":"Llewelyn","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-4","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1542\/peds.105.5.e60","article-title":"Invasive group A streptococcal disease in children and association with varicella-zoster virus infection","volume":"105","author":"Laupland","year":"2000","journal-title":"Pediatrics"},{"key":"key-10.1136\/archdischild-2015-310121-5","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1542\/peds.105.5.e60","article-title":"Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario group A streptococcal study group","volume":"105","author":"Laupland","year":"2000","journal-title":"Pediatrics"},{"key":"key-10.1136\/archdischild-2015-310121-6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00431-010-1337-x","article-title":"Clinical characteristics of children with group A streptococcal toxic shock syndrome admitted to pediatric intensive care units","volume":"170","author":"Rodr\u00edguez-Nu\u00f1ez","year":"2011","journal-title":"Eur J Pediatr"},{"key":"key-10.1136\/archdischild-2015-310121-7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/606048","article-title":"Intravenous immunoglobulin in children with streptococcal toxic shock syndrome","volume":"49","author":"Shah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/archdischild-2013-304741","article-title":"Toxic shock syndrome surveillance in UK children","volume":"99","author":"Adalat","year":"2014","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2015-310121-9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/archdischild-2014-306601","article-title":"Toxic shock syndrome: under-recognised and under-treated?","volume":"99","author":"Curtis","year":"2014","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2015-310121-10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/cid\/ciu304","article-title":"Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A streptococcal infections","volume":"59","author":"Carapetis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3201\/eid1402.070888","article-title":"Severe streptococcus pyogenes infections, United Kingdom, 2003\u20132004","volume":"14","author":"Lamagni","year":"2008","journal-title":"Emerging Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1086\/341409","article-title":"Epidemiology of invasive group a streptococcus disease in the United States, 1995\u20131999","volume":"35","author":"O'Brien","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-13","first-page":"1","article-title":"Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention","volume":"46","year":"1997","journal-title":"MMWR Recomm Rep"},{"key":"key-10.1136\/archdischild-2015-310121-14","unstructured":"Australian Bureau of Statistics. Census Quick Stats. http:\/\/www.censusdata.abs.gov.au\/census_services\/getproduct\/census\/2011\/quickstat\/2?opendocument&navpos=220 (accessed 6 July 2015)."},{"key":"key-10.1136\/archdischild-2015-310121-15","doi-asserted-by":"crossref","first-page":"e22997","DOI":"10.1371\/journal.pone.0022997","article-title":"Staphylococcal toxic shock syndrome 2000\u20132006: epidemiology, clinical features, and molecular characteristics","volume":"6","author":"DeVries","year":"2011","journal-title":"PLoS ONE"},{"key":"key-10.1136\/archdischild-2015-310121-16","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/adc.2007.123232","article-title":"Severe complications of chickenpox in hospitalised children in the UK and Ireland","volume":"92","author":"Cameron","year":"2007","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2015-310121-17","unstructured":"Department of Health State Government of Victoria. Immunisation. http:\/\/www.health.vic.gov.au\/immunisation\/resources\/history.htm (accessed 4 Aug 2015)."},{"key":"key-10.1136\/archdischild-2015-310121-18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0885066613517069","article-title":"Successful use of extracorporeal membrane oxygenation in an adult patient with toxic shock-induced heart failure","volume":"30","author":"Gabel","year":"2015","journal-title":"J Intensive Care Med"},{"key":"key-10.1136\/archdischild-2015-310121-19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jpc.12601","article-title":"Severe group A streptococcal infections in a paediatric intensive care unit","volume":"50","author":"Lithgow","year":"2014","journal-title":"J Paediatr Child Health"},{"key":"key-10.1136\/archdischild-2015-310121-20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/dkl173","article-title":"Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation","volume":"58","author":"Sriskandan","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key-10.1136\/archdischild-2015-310121-21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/376630","article-title":"Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a european randomized, double-blind, placebo-controlled trial","volume":"37","author":"Darenberg","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2165\/11634180-000000000-00000","article-title":"Invasive group A streptococcal disease","volume":"72","author":"Steer","year":"2012","journal-title":"Drugs"},{"key":"key-10.1136\/archdischild-2015-310121-23","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/515199","article-title":"Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome\u2014a comparative observational study","volume":"28","author":"Kaul","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/cid\/ciu449","article-title":"Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study","volume":"59","author":"Linn\u00e9r","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.1136\/archdischild-2015-310121-25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/JB.137.2.1022-1023.1979","article-title":"Differential inhibition of bacterial growth and hemolysin production by lincosamide antibiotics","volume":"137","author":"Shibl","year":"1979","journal-title":"J Bacteriol"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2015-310121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T10:58:56Z","timestamp":1601117936000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2015-310121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,26]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,7,19]]},"published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1136\/archdischild-2015-310121"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2015-310121","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,26]]}}}